Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentations and Posters at 12th Annual WORLDSymposium™ 2016

CRANBURY, N.J., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3...
February 09, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Strengthens Executive Leadership Team

CRANBURY, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has strengthened its...
February 03, 2016 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference

CRANBURY, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that John F. Crowley,...
January 11, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Provides Full-Year 2016 Strategic Outlook and Financial Guidance

Migalastat for Fabry Disease Moving Toward CHMP Opinion in European Union Pompe Disease Clinical Study Initiated to Investigate Novel Enzyme Replacement Therapy Epidermolysis Bullosa...
January 04, 2016 16:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference and 3rd Annual Dermatology Summit

CRANBURY, N.J., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that the Company will...
December 22, 2015 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease

IND Open and Clinical Sites Being Initiated First Amicus Proprietary Biologic to Enter Clinic CRANBURY, N.J., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a...
November 12, 2015 16:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Goldman Sachs US Emerging / SMID Cap Growth Conference

CRANBURY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief...
November 03, 2015 16:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Third Quarter 2015 Financial Results and Corporate Updates

Migalastat for Fabry Disease Moving Forward to CHMP Opinion in European Union Novel Pompe ERT Advancing to Enter Phase 1/2 Study in Pompe Patients Rolling NDA Now Initiated for SD-101 for...
October 27, 2015 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Third Quarter 2015 Financial Results on November 3, 2015

CRANBURY, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, November 3, 2015 at 4:30 p.m. ET to discuss...
October 02, 2015 10:39 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Host FDA Update Conference Call Today

CRANBURY, N.J., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, announced that in follow-up to...